Compare Danaher Corporation (DHR) vs Goldman Sachs Group Inc (GS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Goldman Sachs Group Inc — how do they compare? Danaher Corporation trades at $217.43 (market cap $152.87B), while Goldman Sachs Group Inc trades at $886 (market cap $256.98B). The key difference: Goldman Sachs Group Inc is the larger of the two by market cap, and Goldman Sachs Group Inc pays the higher dividend (2.27%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Goldman Sachs Group Inc for 101 Days on average.
| DHR | GS | |
|---|---|---|
Market Cap | $152.87B | $256.98B |
Volume | 5,228,698 | 1,748,426 |
Sector | Health | Financials |
52-Week High | $242.05 | $1.15K |
52-Week Low | $161.91 | $744.60 |
Typical Hold Time | 69 Days | 101 Days |
Enterprise Value | $175.08B | $814.98B |
Dividend Yield | 0.74% | 2.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Goldman Sachs (GS) trades at $882.59, down 1.63% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $20.98 versus $14.47 expected. Revenue growth accelerated to $58.28B in 2025 with net income margin improving to 31.68%. Recent news highlights the company's focus on expanding to a $70B revenue base and AI initiatives.
The outlook remains positive with analyst consensus target of $1,130 representing 28% upside potential. Key risks include volatile cash flows with negative operating cash of -$45.15B in 2025 and potential FICC business softness. The current valuation at P/E of 13.7 appears attractive relative to earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Goldman Sachs Group Inc
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →
